OriBase Pharma Scientific Approach
OriBase Pharma scientific approach is based on the development of new and targeted therapies, which has demonstrated over last years to be the most relevant approach (in terms of efficacy and safety) in oncology new drug development over the lattest years.
OriBase Pharma team has developed across the years a sound knowledge in cancer biology with pronounced interest and expertise in the field of kinase inhibitors. The current popularity of kinases as drug targets (at least 15 kinase inhibitors are marketed) is driven by the convergence of several factors:
- Firstly, with approximately 518 kinases encoded in the human genome, virtually every signal transduction process is wired by through a phosphotransfer cascade, suggesting that inhibition of kinase activity can elicit a real physiological response.
- Secondly, despite a high degree of conservation in the ATP binding site, highly selective small molecules with favorable pharmaceutical properties can be developed.
- Thirdly, surprisingly, inhibition of kinase activity in normal cells can often be tolerated, presenting a therapeutic window for the selective killing of tumor cells.
- Finally, several kinase inhibitors have shown a high-profile success, exhibiting high response rates mainly in cancerous patients.
In contrast to conventional cytotoxic chemotherapy & radiation therapy, OriBase Pharma next generation kinase therapeutics target specific tumor cells. New therapies developed by OriBase Pharma fight cancer with multi-site mechanism of action and reduce mechanisms leading to drug-resistance.